BBIO:NSD-BridgeBio Pharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 38.34

Change

+0.32 (+0.84)%

Market Cap

USD 6.43B

Volume

2.26M

Analyst Target

USD 44.45
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.03 (-0.46%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.86 (-0.38%)

USD 65.38B
ARGX argenx NV ADR

+7.09 (+1.24%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+0.88%)

USD 32.75B
ONC BeiGene, Ltd.

-1.27 (-0.49%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.31 (+0.93%)

USD 18.35B
SMMT Summit Therapeutics PLC

+0.17 (+0.87%)

USD 13.53B
INSM Insmed Inc

-0.95 (-1.29%)

USD 11.84B
INCY Incyte Corporation

-0.18 (-0.27%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.84 (-1.50%)

USD 11.29B

ETFs Containing BBIO

LFSC F/m Emerald Life Sciences.. 6.87 % 0.00 %

+0.05 (+0.19%)

USD 0.05B
BBP Virtus LifeSci Biotech Pr.. 2.16 % 0.79 %

+0.20 (+0.19%)

USD 0.02B
XEXP:CA iShares Exponential Techn.. 0.72 % 0.00 %

+0.40 (+0.19%)

CAD 0.02B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.72% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.72% 88% B+ 91% A-
Trailing 12 Months  
Capital Gain 41.37% 85% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.37% 85% B 85% B
Trailing 5 Years  
Capital Gain 31.84% 83% B 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.84% 82% B 57% F
Average Annual (5 Year Horizon)  
Capital Gain 36.52% 77% C+ 86% B+
Dividend Return 36.52% 77% C+ 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 109.16% 33% F 18% F
Risk Adjusted Return 33.45% 87% B+ 68% D+
Market Capitalization 6.43B 97% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.